Maria Richards-Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Richards-Brown has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Daniele Panconesi
Division of Psychiatry, University College London, London, United Kingdom
4 shared publicationsMarius Cotic
Division of Psychiatry, University College London, London, United Kingdom
4 shared publicationsNoushin Saadullah Khani
Division of Psychiatry, University College London, London, United Kingdom
4 shared publicationsRosemary Abidoph
Division of Psychiatry, University College London, London, United Kingdom
4 shared publications- Alvin Richards-Belle
Division of Psychiatry, University College London, London, UK
3 shared publications - Daisy Mills
Division of Psychiatry, University College London, London, UK
3 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (6) , e268
Ethnic disparities in time to bipolar disorder diagnosis: retrospective cohort study
Summary: Lithium is a first-line maintenance treatment for bipolar disorder yet delays in diagnosis and lithium initiation remain common. This retrospective cohort study examined whether time to bipolar disorder diagnosis and lithium initiation differ by ethnicity, gender or age among 88 patients at South London and Maudsley National Health Service Foundation Trust. Delay outcomes were non-normally distributed and log-transformed before analysis. No demographic characteristic was significantly associated with time to lithium initiation. Ethnicity was significantly associated with diagnostic delay, with individuals from minority ethnic groups experiencing longer delays than White individuals (median 556 v . 50.5 days; IQR [89.8, 1342] v . [6.25, 222]), which persisted after adjustment for age, gender, substance use and illness severity, and remained robust to outlier removal. Although social deprivation was not accounted for, these findings suggest possible systematic diagnostic inequities in bipolar disorder, calling for culturally informed diagnostic practices and further investigation in larger, multi-site samples.
- 19 October 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (6) , e268
Open AccessEthnic disparities in time to bipolar disorder diagnosis: retrospective cohort study
Summary: Lithium is a first-line maintenance treatment for bipolar disorder yet delays in diagnosis and lithium initiation remain common. This retrospective cohort study examined whether time to bipolar disorder diagnosis and lithium initiation differ by ethnicity, gender or age among 88 patients at South London and Maudsley National Health Service Foundation Trust. Delay outcomes were non-normally distributed and log-transformed before analysis. No demographic characteristic was significantly associated with time to lithium initiation. Ethnicity was significantly associated with diagnostic delay, with individuals from minority ethnic groups experiencing longer delays than White individuals (median 556 v . 50.5 days; IQR [89.8, 1342] v . [6.25, 222]), which persisted after adjustment for age, gender, substance use and illness severity, and remained robust to outlier removal. Although social deprivation was not accounted for, these findings suggest possible systematic diagnostic inequities in bipolar disorder, calling for culturally informed diagnostic practices and further investigation in larger, multi-site samples.
- Open Access
- 22 June 2026
- Published by SAGE Publications in Quarterly Journal of Experimental Psychology
EXPRESS: Exaggerated Self-Referencing in Body Dysmorphic Disorder
The self-prioritisation effect demonstrates that people have a bias to learn and process self-relevant compared to other-relevant information. This tendency may provide a tool to understand how body image and perception become disrupted in people with such a pre-occupation with self-related perceptions, behaviours, and affect (Body Dysmorphic Disorder (BDD)). Using an associative learning matching paradigm, participants were presented with geometric shapes that were paired with either themself, a named friend, or an unnamed stranger. Participants were presented with different label-shape pairings and indicated ‘match’ or ‘mismatch’ to the original associations. In Experiment 1, higher BDDQ scores were significantly associated with improved accuracy in identifying the self-related association compared with the Stranger association, Friend was intermediate. Experiment 2 showed that higher BDDQ scores were significantly associated with improved accuracy in identifying ‘You’ matches compared to ‘Friend’ matches as well as an effect found in Reaction Time that was not found in Experiment 1. Across both experiments, higher BDDQ scores were significantly associated with overall faster reaction times. In Experiment 2 we assessed whether the reaction time effects were related to impulsivity and depression for which we found no evidence. We discuss these results in relation to the exaggerated salience that person centred cues may play in BDD and show how this process extends to new learning of self-related cues.
- 22 June 2026
- Published by SAGE Publications in Quarterly Journal of Experimental Psychology
Open AccessEXPRESS: Exaggerated Self-Referencing in Body Dysmorphic Disorder
The self-prioritisation effect demonstrates that people have a bias to learn and process self-relevant compared to other-relevant information. This tendency may provide a tool to understand how body image and perception become disrupted in people with such a pre-occupation with self-related perceptions, behaviours, and affect (Body Dysmorphic Disorder (BDD)). Using an associative learning matching paradigm, participants were presented with geometric shapes that were paired with either themself, a named friend, or an unnamed stranger. Participants were presented with different label-shape pairings and indicated ‘match’ or ‘mismatch’ to the original associations. In Experiment 1, higher BDDQ scores were significantly associated with improved accuracy in identifying the self-related association compared with the Stranger association, Friend was intermediate. Experiment 2 showed that higher BDDQ scores were significantly associated with improved accuracy in identifying ‘You’ matches compared to ‘Friend’ matches as well as an effect found in Reaction Time that was not found in Experiment 1. Across both experiments, higher BDDQ scores were significantly associated with overall faster reaction times. In Experiment 2 we assessed whether the reaction time effects were related to impulsivity and depression for which we found no evidence. We discuss these results in relation to the exaggerated salience that person centred cues may play in BDD and show how this process extends to new learning of self-related cues.
- Open Access
- 9 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1689300
Patient and clinician perspectives on pharmacogenetic testing for antipsychotics
Background/objectives: Medications to treat psychosis (i.e., antipsychotics) have common and sometimes serious adverse drug reactions and can require several trials before finding a suitable drug and dose. To address this, there is increasing focus on personalizing medicine. Pharmacogenetics investigates how genetic variation influences drug metabolism and response, with recent clinical trials suggesting pharmacogenetic testing can improve remission and reduce adverse drug reactions. Therefore, understanding stakeholder perspectives on acceptability is critical.Methods: This pilot study is part of ‘GEMS’ (Genetics and Environment in Mental Health Study), which investigates pharmacogenetic testing for psychosis. A participant survey, co-created with patients, was completed by 22 patient-participants, and semi-structured interviews were conducted with 11 clinician-participants who had used pharmacogenetic test reports with patients.Results: Both patients and clinicians were generally positive about pharmacogenetics, although clinicians saw this as just one component in the multifactorial process of individualized prescribing. Clinicians and patients both suggested a more user-friendly format of the pharmacogenetic report to enhance patient understanding. Some described the reports as promoting more collaborative care, but this was not universal. Clinicians highlighted both retrospective and prospective value in pharmacogenetics providing more certainty through reducing ‘trial-and-error’ prescribing. However, accessibility, understanding, and logistics were identified as potential barriers to implementation.Conclusion: Among patients and clinicians who have experienced pharmacogenetic testing to inform antipsychotic prescribing, acceptability is good. There is potential for pharmacogenetics to enhance personalized prescribing, but barriers to widespread implementation remain.
- 9 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1689300
Open AccessPatient and clinician perspectives on pharmacogenetic testing for antipsychotics
Background/objectives: Medications to treat psychosis (i.e., antipsychotics) have common and sometimes serious adverse drug reactions and can require several trials before finding a suitable drug and dose. To address this, there is increasing focus on personalizing medicine. Pharmacogenetics investigates how genetic variation influences drug metabolism and response, with recent clinical trials suggesting pharmacogenetic testing can improve remission and reduce adverse drug reactions. Therefore, understanding stakeholder perspectives on acceptability is critical.Methods: This pilot study is part of ‘GEMS’ (Genetics and Environment in Mental Health Study), which investigates pharmacogenetic testing for psychosis. A participant survey, co-created with patients, was completed by 22 patient-participants, and semi-structured interviews were conducted with 11 clinician-participants who had used pharmacogenetic test reports with patients.Results: Both patients and clinicians were generally positive about pharmacogenetics, although clinicians saw this as just one component in the multifactorial process of individualized prescribing. Clinicians and patients both suggested a more user-friendly format of the pharmacogenetic report to enhance patient understanding. Some described the reports as promoting more collaborative care, but this was not universal. Clinicians highlighted both retrospective and prospective value in pharmacogenetics providing more certainty through reducing ‘trial-and-error’ prescribing. However, accessibility, understanding, and logistics were identified as potential barriers to implementation.Conclusion: Among patients and clinicians who have experienced pharmacogenetic testing to inform antipsychotic prescribing, acceptability is good. There is potential for pharmacogenetics to enhance personalized prescribing, but barriers to widespread implementation remain.
- Open Access
- 14 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 892
Effect of CYP1A2, CYP2D6, and CYP3A4 Variation on Antipsychotic Treatment Outcomes
Background/Objectives: Antipsychotic treatment response varies considerably between individuals, with one potential reason being genetic variation affecting the cytochrome P450 enzymes that metabolise them. Methods: With a diverse sample of 453 participants, we studied the influence of CYP1A2, CYP2D6, and CYP3A4 variation on three antipsychotic treatment outcomes: participant-reported adverse antipsychotic drug reactions, health-related quality of life, and the dose of antipsychotic medication prescribed. These measures were taken from the baseline assessment, before a pharmacogenetic intervention was delivered. Results: Over half of our sample (62.9%) were carriers of an allele associated with altered metabolism of antipsychotic medications on CYP2D6 or CYP3A4, the two genes with pharmacogenetic guidelines for antipsychotic medications. Ultrarapid CYP2D6 metabolisers reported significantly lower levels of adverse antipsychotic drug reactions than normal CYP2D6 metabolisers (mean difference: −11.1; 95% confidence interval [CI]: −18.9, −3.3; p = 0.00575). There was also suggestive evidence of lower quality of life scores in those carrying one (mean difference: −0.0863; 95% CI: −0.1806, 0.0081; p = 0.0731) or two copies (mean difference: −0.0803; 95% CI: −0.1734, 0.0129; p = 0.0914) of the CYP1A2*30-inducible allele. Conclusions: Our findings suggest that even when looking at a small number of cytochrome P450 genes, carrying an allele associated with altered antipsychotic medication metabolism is relatively common. We also found evidence that the CYP genotype can influence antipsychotic treatment outcomes, specifically adverse drug reactions and quality of life scores.
- 14 June 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 892
Open AccessEffect of CYP1A2, CYP2D6, and CYP3A4 Variation on Antipsychotic Treatment Outcomes
Background/Objectives: Antipsychotic treatment response varies considerably between individuals, with one potential reason being genetic variation affecting the cytochrome P450 enzymes that metabolise them. Methods: With a diverse sample of 453 participants, we studied the influence of CYP1A2, CYP2D6, and CYP3A4 variation on three antipsychotic treatment outcomes: participant-reported adverse antipsychotic drug reactions, health-related quality of life, and the dose of antipsychotic medication prescribed. These measures were taken from the baseline assessment, before a pharmacogenetic intervention was delivered. Results: Over half of our sample (62.9%) were carriers of an allele associated with altered metabolism of antipsychotic medications on CYP2D6 or CYP3A4, the two genes with pharmacogenetic guidelines for antipsychotic medications. Ultrarapid CYP2D6 metabolisers reported significantly lower levels of adverse antipsychotic drug reactions than normal CYP2D6 metabolisers (mean difference: −11.1; 95% confidence interval [CI]: −18.9, −3.3; p = 0.00575). There was also suggestive evidence of lower quality of life scores in those carrying one (mean difference: −0.0863; 95% CI: −0.1806, 0.0081; p = 0.0731) or two copies (mean difference: −0.0803; 95% CI: −0.1734, 0.0129; p = 0.0914) of the CYP1A2*30-inducible allele. Conclusions: Our findings suggest that even when looking at a small number of cytochrome P450 genes, carrying an allele associated with altered antipsychotic medication metabolism is relatively common. We also found evidence that the CYP genotype can influence antipsychotic treatment outcomes, specifically adverse drug reactions and quality of life scores.
- Open Access
- 16 December 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 546
Hearing problems in humans and mouse models with rare copy number variants associated with schizophrenia: a scoping review protocol
Background Hearing loss is a risk factor for developing auditory hallucinations and other psychosis symptoms. To date, very little research has investigated hearing loss in individuals with a high genetic risk of developing schizophrenia and other types of psychosis. 13 copy number variant (CNV) loci are robustly associated with an increased risk of schizophrenia. Of these, microdeletions at 22q11.2 often lead to some hearing loss, and mouse models of this CNV display impaired auditory functioning. We hypothesise that individuals who have a high genetic risk of schizophrenia may also experience hearing problems. This scoping review will explore whether the 13 schizophrenia-associated CNVs are related to hearing problems, including peripheral hearing loss and other auditory problems, in humans and related mouse models. Methods Our scoping review will follow guidelines provided by the Joanna Briggs Institute and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. A systematic search will be completed using PubMed (MEDLINE), Embase, PsychINFO, and Cochrane Library databases, as well as other sources to identify relevant grey literature. Search terms will include all commonly used synonyms for hearing loss and problems with auditory perception, and both human and mouse studies that describe relevant CNVs will be included. Search lists will be screened by two authors independently, according to eligibility criteria, and data will be extracted and summarised using a narrative approach. Conclusions To our knowledge, this will be the first scoping review to explore auditory functioning across all CNVs that confer high schizophrenia risk. Looking ahead, if hearing problems are a clinical feature in these groups (including humans and related mouse models), they may serve as useful genetic models for future mechanistic studies.
- 16 December 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 546
Open AccessHearing problems in humans and mouse models with rare copy number variants associated with schizophrenia: a scoping review protocol
Background Hearing loss is a risk factor for developing auditory hallucinations and other psychosis symptoms. To date, very little research has investigated hearing loss in individuals with a high genetic risk of developing schizophrenia and other types of psychosis. 13 copy number variant (CNV) loci are robustly associated with an increased risk of schizophrenia. Of these, microdeletions at 22q11.2 often lead to some hearing loss, and mouse models of this CNV display impaired auditory functioning. We hypothesise that individuals who have a high genetic risk of schizophrenia may also experience hearing problems. This scoping review will explore whether the 13 schizophrenia-associated CNVs are related to hearing problems, including peripheral hearing loss and other auditory problems, in humans and related mouse models. Methods Our scoping review will follow guidelines provided by the Joanna Briggs Institute and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. A systematic search will be completed using PubMed (MEDLINE), Embase, PsychINFO, and Cochrane Library databases, as well as other sources to identify relevant grey literature. Search terms will include all commonly used synonyms for hearing loss and problems with auditory perception, and both human and mouse studies that describe relevant CNVs will be included. Search lists will be screened by two authors independently, according to eligibility criteria, and data will be extracted and summarised using a narrative approach. Conclusions To our knowledge, this will be the first scoping review to explore auditory functioning across all CNVs that confer high schizophrenia risk. Looking ahead, if hearing problems are a clinical feature in these groups (including humans and related mouse models), they may serve as useful genetic models for future mechanistic studies.
- 16 October 2024
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 87, 249
F81. IMPLEMENTING ACKR1 VARIANT TESTING IN ENGLAND FOR CLOZAPINE THERAPY
- 16 October 2024
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 87, 249
F81. IMPLEMENTING ACKR1 VARIANT TESTING IN ENGLAND FOR CLOZAPINE THERAPY
- Open Access
- 24 September 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 546
Hearing problems in humans and mouse models with rare copy number variants associated with schizophrenia: a scoping review protocol
Background Hearing loss is a risk factor for developing auditory hallucinations and other psychosis symptoms. To date, very little research has investigated hearing loss in individuals with a high genetic risk of developing schizophrenia and other types of psychosis. 13 copy number variant (CNV) loci are robustly associated with an increased risk of schizophrenia. Of these, microdeletions at 22q11.2 often lead to some hearing loss, and mouse models of this CNV display impaired auditory functioning. We hypothesise that hearing impairment is an understudied mechanism that contributes to the formation of psychosis symptoms in individuals at high genetic risk. This scoping review will explore whether the 13 schizophrenia-associated CNVs are related to hearing problems, including peripheral hearing loss and other auditory problems, in humans and related mouse models. Methods Our scoping review will follow guidelines provided by the Joanna Briggs Institute and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. A systematic search will be completed using PubMed (MEDLINE), Embase, PsychINFO, and Cochrane Library databases, as well as other sources to identify relevant grey literature. Search terms will include all commonly used synonyms for hearing loss and problems with auditory perception, and both human and mouse studies that describe relevant CNVs will be included. Search lists will be screened by two authors independently, according to eligibility criteria, and data will be extracted and summarised using a narrative approach, and meta-analysis methods will be used if possible. Conclusions To our knowledge, this will be the first scoping review to explore auditory functioning across all CNVs that confer high schizophrenia risk. Looking ahead, if hearing problems are a clinical feature in these groups (including humans and related mouse models), they may serve as useful genetic models for future mechanistic studies.
- 24 September 2024
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 546
Open AccessHearing problems in humans and mouse models with rare copy number variants associated with schizophrenia: a scoping review protocol
Background Hearing loss is a risk factor for developing auditory hallucinations and other psychosis symptoms. To date, very little research has investigated hearing loss in individuals with a high genetic risk of developing schizophrenia and other types of psychosis. 13 copy number variant (CNV) loci are robustly associated with an increased risk of schizophrenia. Of these, microdeletions at 22q11.2 often lead to some hearing loss, and mouse models of this CNV display impaired auditory functioning. We hypothesise that hearing impairment is an understudied mechanism that contributes to the formation of psychosis symptoms in individuals at high genetic risk. This scoping review will explore whether the 13 schizophrenia-associated CNVs are related to hearing problems, including peripheral hearing loss and other auditory problems, in humans and related mouse models. Methods Our scoping review will follow guidelines provided by the Joanna Briggs Institute and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. A systematic search will be completed using PubMed (MEDLINE), Embase, PsychINFO, and Cochrane Library databases, as well as other sources to identify relevant grey literature. Search terms will include all commonly used synonyms for hearing loss and problems with auditory perception, and both human and mouse studies that describe relevant CNVs will be included. Search lists will be screened by two authors independently, according to eligibility criteria, and data will be extracted and summarised using a narrative approach, and meta-analysis methods will be used if possible. Conclusions To our knowledge, this will be the first scoping review to explore auditory functioning across all CNVs that confer high schizophrenia risk. Looking ahead, if hearing problems are a clinical feature in these groups (including humans and related mouse models), they may serve as useful genetic models for future mechanistic studies.